Low-dose Pill reduces ovarian cancer risk

	Tweet

Oral contraceptives with low levels of estrogen and progestin reduce the risk of ovarian cancer even more than older versions of the ‘Pill’, according to investigators at the University of Hawaii in Honolulu.

The benefits of oral contraceptive pills in protecting against ovarian cancer have long been recognized, Dr. Galina Lurie and her colleagues note in their report in the medical journal Obstetrics & Gynecology. However, over the last 30 years the doses of hormones in the pills have been decreased, to reduce side effects. 

To see how this might have affected ovarian cancer risk, Lurie’s group conducted a population-based study in Hawaii and Los Angeles involving 745 women diagnosed with ovarian cancer and a comparison group of 943 women matched by age and ethnicity and who were free of cancer.

Health information was collected by standard questionnaires, and interviewers used photo albums to help participants identify the specific oral contraceptive pills they had used.

Overall, women who had used any oral contraceptive had a 50 percent reduction in the risk of developing ovarian cancer than women who had never taken the Pill, the investigators report.

However, the risk was reduced by 38 percent for women who took high estrogen and high progestin pills, while the risk reduction was 81 percent for those taking pills with low levels of both hormones.

“Up to 42 percent of ovarian cancers might have been avoided if all women used some form of combined oral contraceptive pills,” Lurie and her associates calculate.

Furthermore, they say, “An estimated 73 percent of ovarian cancers might have been avoided if all women used oral contraceptive pill formulation of low estrogen and low progestin.”

SOURCE: Obstetrics & Gynecology, March 2007. 

RELATED STORIES:
Vaccine/Antibody Therapy Effective in Melanoma and Ovarian Cancer   Possible New Therapy for Patients with Platinum-Resistant Ovarian Cancer   Short-term OC use cuts ovarian cancer risk   Analgesic drugs don’t reduce ovarian cancer risk   Research Highlights Important Indicators of Early-stage Ovarian Cancer   Survivors of Rare Ovarian Cancer Retain Fertility, Have Positive Relationships   First baby is born after a new technique -Ovarian transplantation   Angiogenesis Linked to Poor Survival in Patients with Rare Type of Ovarian Cancer   Commercial Sale of Ovarian Cancer Test Deemed Illegal by FDA   65% of ovarian cancer cells sideline body’s defences   More study needed on vitamin D-ovarian cancer link   Correlation Between ChemoFx Assay and Improved Survival in Patients with Ovarian Cancer   Finding ovarian cancer fast may not help survival   Ovarian cancer subtypes are different diseases: Implications for biomarker studies   Late-Stage Ovarian Cancer Therapy Shows Promise in Phase I Trial   Hormone Therapy Use Linked With Increased Risk of Ovarian Cancer   Abdominal chemotherapy boosts survival in ovarian cancer patients   Folate receptors may serve as a front door to ovarian cancer treatment   Young early stage ovarian cancer patients can preserve fertility   Removal of Ovaries Decreases Cancer Risk for Women at High-Risk   Selumetinib Controlled Recurrent Low-Grade Serous Ovarian Cancer   Cancer-Reducing Benefits of Preventive Surgery May Be Specific to Gene Mutation

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]